Originalus straipsnis ČIA
For the full-year 2021, Pfizer increased revenue guidance to $78bn-$80bn, including about $33.5bn from Covid-19 vaccine sales.
Pfizer has reported a 92% increase in revenue to $19bn in the second quarter (Q2) of 2021, compared to $9.86bn in the Q2 last year.
The operational rise in revenue was 86% or $8.5bn for Q2 ended 04 July 2021.
On excluding Covid-19 vaccine, BNT162b2, revenues increased to $11.1bn, reflecting 10% operational growth. Pfizer co-developed the vaccine with BioNTech.
Pfizer noted that this operational growth excluding the Covid-19 vaccine in Q2 2021 builds on the operational growth of 6% recorded by a similar business last year.
The reported diluted earnings per share (EPS) was $0.98 in the Q2 of 2021, a surge of 58% compared to $0.62 during the year-ago quarter.
Adjusted diluted EPS was $1.07 in the second quarter of this year, indicating a 73% increase from $0.62 in Q2 2020.
Pfizer Global Supply executive vice-president and chief financial officer Frank D’Amelio said: “Pfizer’s second-quarter performance highlighted once again the underlying strength of our business, with consistent and solid growth coming from multiple products and categories.
“It is important to point out that the 10% year-over-year (YOY) operational revenue growth rate for our business excluding BNT162b2 comes on top of a strong 6% operational growth rate delivered by the comparable business in the second quarter of last year.”